Johann de Bono

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
    G Attard
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Cancer 97:1338-43. 2007
  2. pmc Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
    A H M Reid
    The Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK
    Br J Cancer 102:678-84. 2010
  3. pmc Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
    G Attard
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 95:767-74. 2006
  4. pmc CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
    J E Ang
    The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 100:671-5. 2009
  5. ncbi request reprint Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer
    Johann Sebastian de Bono
    Drug Development Unit and Department of Academic Urology, Royal Marsden Hospital, Centre for Cancer Therapeutics, Institute for Cancer Research, Surrey, United Kingdom
    J Clin Oncol 25:257-62. 2007
  6. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
    Johann S de Bono
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey, UK
    Clin Cancer Res 14:6663-73. 2008
  7. ncbi request reprint Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
  8. ncbi request reprint Drugging cell cycle kinases in cancer therapy
    S Blagden
    Centre for Cancer Therapeutics, Institute for Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England
    Curr Drug Targets 6:325-35. 2005
  9. ncbi request reprint Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
    J S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Ann Oncol 15:1825-33. 2004
  10. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012

Collaborators

Detail Information

Publications41

  1. pmc A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
    G Attard
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Cancer 97:1338-43. 2007
    ..There were no pharmacokinetic drug-drug interactions. The recommended phase II dose of this combination was docetaxel 75 mg m(-2) and 420 mg pertuzumab following a loading dose of 840 mg...
  2. pmc Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
    A H M Reid
    The Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK
    Br J Cancer 102:678-84. 2010
    ..The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 gene rearrangements and PTEN gene loss status...
  3. pmc Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
    G Attard
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 95:767-74. 2006
    ..Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes (ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease...
  4. pmc CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
    J E Ang
    The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Br J Cancer 100:671-5. 2009
    ....
  5. ncbi request reprint Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer
    Johann Sebastian de Bono
    Drug Development Unit and Department of Academic Urology, Royal Marsden Hospital, Centre for Cancer Therapeutics, Institute for Cancer Research, Surrey, United Kingdom
    J Clin Oncol 25:257-62. 2007
    ..To determine the prostate-specific antigen (PSA) 50% decline rate within 24 weeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory prostate cancer (HRPC)...
  6. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
    Johann S de Bono
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey, UK
    Clin Cancer Res 14:6663-73. 2008
    ..To determine the safety, maximum tolerated dose, and pharmacokinetic-pharmacodynamic profile of a histone deacetylase inhibitor, LAQ824, in patients with advanced malignancy...
  7. ncbi request reprint Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
    ..Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points...
  8. ncbi request reprint Drugging cell cycle kinases in cancer therapy
    S Blagden
    Centre for Cancer Therapeutics, Institute for Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, England
    Curr Drug Targets 6:325-35. 2005
    ..The outcome of early clinical trials involving these agents is awaited, but these certainly represent a promising new area of anticancer drug development...
  9. ncbi request reprint Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity
    J S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Ann Oncol 15:1825-33. 2004
    ....
  10. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
    ..We describe methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned intermediate analysis and (2) adding a new research arm during the trial...
  11. ncbi request reprint Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
    ..This provided the rationale for the three-times weekly treatment explored in this protocol...
  12. doi request reprint 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?
    Hendrik Tobias Arkenau
    Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    Eur J Cancer 44:1536-40. 2008
    ..In order to safeguard the well-being of its participants, a common inclusion criterion is that of life expectancy >3 months. However, previous studies have shown that about 20% of these patients do not survive beyond this time-point...
  13. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007
    ..Pemetrexed plasma pharmacokinetics were evaluated for cycle 1...
  14. doi request reprint A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition
    Andre T Brunetto
    Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Eur J Cancer 46:2739-45. 2010
    ..Unplanned hospital admissions (UHAs) in the context of oncology Phase I trials are important, yet rarely reported...
  15. ncbi request reprint A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 13:532-9. 2007
    ..The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies...
  16. ncbi request reprint Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer
    Hendrik Tobias Arkenau
    Drug Development Unit, Royal Marsden Hospital, London and Surrey, UK
    Oncology 76:151-6. 2009
    ..However, even after intensive treatment, most tumors will subsequently progress and some patients are offered experimental phase I therapies...
  17. ncbi request reprint Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Alison Reid
    Royal Marsden Hospital, The Institute of Cancer Research, Centre for Cancer Therapeutics, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 43:481-9. 2007
    ..Other agents include BIBW-2992 and HKI-272, irreversible TKIs of EGFR and HER2, and pertuzumab, a heterodimerisation inhibitor of EGFR and HER2...
  18. doi request reprint Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies
    Lisa A Hammond-Thelin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Invest New Drugs 30:316-26. 2012
    ..This study was performed to principally evaluate the feasibility of administering TAS-106 as a bolus intravenous (IV) infusion every 3 weeks...
  19. doi request reprint Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
    Sophie Postel-Vinay
    Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom
    J Clin Oncol 29:1728-35. 2011
    ....
  20. doi request reprint Prospective validation of a prognostic score to improve patient selection for oncology phase I trials
    Hendrik Tobias Arkenau
    Royal Marsden Hospital and Institute of Cancer Research, Drug Development Unit, Sutton, UK
    J Clin Oncol 27:2692-6. 2009
    ..This prospective study was performed to test the validity of the prognostic score...
  21. ncbi request reprint Management of patients with castration-resistant disease
    Carmel Pezaro
    Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Hematol Oncol Clin North Am 27:1243-60, ix. 2013
    ..This article summarizes clinical data and unresolved issues in the use of current and emerging CRPC therapies. ..
  22. ncbi request reprint Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
    Quincy S C Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    J Clin Oncol 25:3753-8. 2007
    ..This phase I trial (EGF10005) assessed the safety, optimally tolerated regimen (OTR), and pharmacokinetics of lapatinib and capecitabine in combination in patients with advanced solid malignancies...
  23. pmc Perceptions and referral trends into phase I oncology trials: results of a clinical survey
    Andre Brunetto
    The Royal Marsden Hospital, Surrey SM2 5PT, UK
    J Oncol 2011:861401. 2011
    ..Outcome reporting can improve communication with ROs and importantly has the potential for better patient selection considered for Phase I oncology trials...
  24. ncbi request reprint Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 24:2052-8. 2006
    ....
  25. doi request reprint Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
    Robin L Jones
    Royal Marsden Hospital, London, SW3 6JJ, UK
    Cancer Chemother Pharmacol 68:423-9. 2011
    ..The aim of this study was to evaluate the clinical benefit for sarcoma patients treated within the Phase I Unit of a single referral centre...
  26. ncbi request reprint Histone deacetylase inhibitors: emerging anticancer therapeutic agents?
    Rebecca Kristeleit
    Institute for Cancer Research and Royal Marsden Hospital, Surrey, UK
    Clin Lung Cancer 7:S19-30. 2005
    ..Successful future development relies on clearer understanding of the dominant mechanisms involved in the observed antiproliferative effects...
  27. ncbi request reprint Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress
    Victor Moreno García
    Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer Discov 1:207-12. 2011
    ..We therefore propose a more efficient parallel predictive biomarker and clinical anticancer drug development process to deal with the obstacles hindering progress...
  28. pmc Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
    Susan Halabi
    Susan Halabi, Andrew J Armstrong, Ellen Kaplan, Chen Yen Lin, and Nicole C Solomon, Duke University, Durham, NC Oliver Sartor, Tulane University, New Orleans, LA Johann de Bono, Royal Marsden Hospital, Sutton, United Kingdom and Eric J Small, University of California at San Francisco, San Francisco, CA
    J Clin Oncol 31:3944-50. 2013
    ..The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy...
  29. ncbi request reprint Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:211-22. 2003
    ..v.) once every 3 weeks and to seek evidence of antitumor activity...
  30. ncbi request reprint Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital
    Vasilios Karavasilis
    Drug Development Unit, Sycamore House, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 44:978-82. 2008
    ..To identify factors that may prevent or delay patients referred for consideration of phase I studies from commencing such a study...
  31. doi request reprint A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours
    Edwina N Scott
    Department of Oncology, University of Leicester, Leicester Royal Infirmary, Leicester, LE1 5WW, England, UK
    Cancer Chemother Pharmacol 64:425-9. 2009
    ....
  32. ncbi request reprint Update on tubulin-binding agents
    Gerhardt Attard
    Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Pathol Biol (Paris) 54:72-84. 2006
    ..In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established...
  33. ncbi request reprint Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib
    Timothy J Graham
    Affiliations of authors Division of Radiotherapy and Imaging TJG, NT, TJS, SPR, Cancer Research UK Cancer Therapeutics Unit GB, MC, SM, GA, JdB, SAE, Fed, and Molecular Pathology FED, Institute of Cancer Research and Royal Marsden NHS Trust, Surrey, UK
    J Natl Cancer Inst 106:dju033. 2014
    ..The therapeutic efficacy of the multikinase inhibitor cabozantinib was assessed in an orthotopic xenograft model of castration-resistant prostate cancer (CRPC) bone metastasis using noninvasive, multimodality functional imaging...
  34. doi request reprint Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
    L Rhoda Molife
    Drug Development Unit, The Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Cancer Chemother Pharmacol 72:1213-22. 2013
    ..Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients...
  35. doi request reprint Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
    Aurelius Omlin
    Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
    Eur Urol 64:300-6. 2013
    ..Prognostic nomograms for survival estimation in CRPC were constructed prior to the introduction of docetaxel and other novel treatments...
  36. doi request reprint Agents that target androgen synthesis in castration-resistant prostate cancer
    Roberta Ferraldeschi
    Institute of Cancer Research, London, United Kingdom
    Cancer J 19:34-42. 2013
    ..Here, we review the discovery and clinical development of abiraterone and other novel androgen-synthesis inhibitors for the management of advanced prostate cancer...
  37. ncbi request reprint Evolution of androgen receptor targeted therapy for advanced prostate cancer
    Yien Ning Sophia Wong
    Prostate Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK
    Nat Rev Clin Oncol 11:365-76. 2014
    ....
  38. ncbi request reprint Expression profiling of CD133+ and CD133- epithelial cells from human prostate
    Christopher J Shepherd
    Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK
    Prostate 68:1007-24. 2008
    ..The aim of our study was to gene expression profile CD133-expressing cells...
  39. ncbi request reprint Making sense of antisense
    Laura Vidal
    Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, London, United Kingdom
    Eur J Cancer 41:2812-8. 2005
    ..The high manufacture cost of these agents, when compared with small chemical molecules, could however, limit their success unless cost-effective manufacturing processes are developed...
  40. doi request reprint Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
    Louise J Barber
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 229:422-9. 2013
    ..These secondary mutations restored full-length BRCA2 protein, and most likely cause olaparib resistance by re-establishing BRCA2 function in the tumour cells...
  41. ncbi request reprint Reovirus: Rationale and clinical trial update
    Rohit Lal
    Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK
    Curr Opin Mol Ther 11:532-9. 2009
    ....